PharmaShots | Incisive News in 3 Shots

Subscribe Now

luster studies

Novartis Terminates Clinical Development of Fevipiprant (AW039) in P-III LUSTER Studies for Patients with Uncontrolled GINA 4/5 Asthma

Novartis Terminates Clinical Development of Fevipiprant (AW039) in P-III LUSTER Studies for Patients with Uncontrolled GINA 4/5 As...

December 16, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us